5 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow Cloudbreak Therapeutics, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of CBT-004 in Patients With Vascularized Pinguecula CBT-004 - Pinguecula | Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 88 | 2023-12-21 | 2025-06-05 |
| Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop CBT-009, Vehicle, Atropine Sulfate - Myopia, Progressive | Phase 1 / Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 84 | 2022-07-20 | 2023-01-27 |
| Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction CBT-008 - Meibomian Gland Dysfunction | Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 95 | 2022-03-04 | 2024-04-24 |
| Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction CBT-006 - Meibomian Gland Dysfunction | Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 92 | 2021-09-05 | 2024-04-24 |
| Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium CBT-001 single dose, Vehicle, CBT-001 Multi-dose - Pterygium | Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 75 | 2017-04-15 | 2020-02-24 |
Meibomian Gland Dysfunction (2) · Myopia, Degenerative (1) · Pinguecula (1) · Pterygium (1)
Atropine (1)
United States (4) · Australia (1)
Bing Leng, MD (1) · John Hovanesian, M.D. (1) · Rong Yang (1) · Tanya Revell, MD (1)